Abstract
Venous thromboembolic disease (VTD) is a common complication associated to greater mortality in patients with cancer. Its etiology is multifactorial and depends on the characteristics and co-morbidities of the patient, the tumor type and extension, and the oncological treatment. The management of VTD is more complex in patients with cancer due to an increased risk of recurrence and major bleeding complications during anticoagulation compared to the general non-oncological population. The above differences have led to the development of specific clinical trials to assess the efficacy and safety of anticoagulant therapy in patients with cancer. The present clinical guidelines are intended to provide general recommendations on the management of cancer-associated VTD according to updated according to the most recent scientific evidence.
Author supplied keywords
Cite
CITATION STYLE
Villalobos, A., Valle, R., Pagán-Escribano, J., Ortiz, M., Demelo-Rodríguez, P., & Font, C. (2025). 2024 Spanish Society of Internal Medicine (SEMI) recommendations for the management of cancer-associated venous thrombosis. Revista Clinica Espanola, 225(1), 35–44. https://doi.org/10.1016/j.rce.2024.09.003
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.